Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs.
A reduced dose (0.1 mL) of intradermal hepatitis A virus (HAV) vaccine could facilitate the control of hepatitis A in countries of endemicity. All study subjects receiving an aluminum-free HAV vaccine intradermally were seroprotected 28 days after vaccination (anti-HAV titer, > or =10 mIU/mL). Seroprotection rates decreased to 80.8% at 12 months but returned to 100%, with titers increasing 28-fold, after receipt of a booster vaccination.
Pancharoen
Chitsanu
C
Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Chitsanu.P@Chula.ac.th
Mekmullica
Jutarat
J
Thisyakorn
Usa
U
Kasempimolporn
Songsri
S
Wilde
Henry
H
Herzog
Christian
C
D000293:Adolescent; D000535:Aluminum / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D005260:Female; D006506:Hepatitis A / Q000517:prevention & control*; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007223:Infant; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D013785:Thailand
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D000535:Aluminum